Novo Nordisk $NVO: Market Underestimates Stronger Weight-Loss Pipeline Against Eli...
In the competitive world of weight-loss drugs, Novo Nordisk's advancements in oral GLP-1 therapies, particularly semaglutide, might be its secret weapon against Eli Lilly. Despite perceptions of falling behind, Novo...